WO2001046473A1 - Traitement de mycobacterium tuberculosis avec des polynucleotides antisens - Google Patents

Traitement de mycobacterium tuberculosis avec des polynucleotides antisens Download PDF

Info

Publication number
WO2001046473A1
WO2001046473A1 PCT/US2000/034688 US0034688W WO0146473A1 WO 2001046473 A1 WO2001046473 A1 WO 2001046473A1 US 0034688 W US0034688 W US 0034688W WO 0146473 A1 WO0146473 A1 WO 0146473A1
Authority
WO
WIPO (PCT)
Prior art keywords
mycobacterium tuberculosis
antisense
polynucleotide
tuberculosis
glutamine synthetase
Prior art date
Application number
PCT/US2000/034688
Other languages
English (en)
Inventor
Marcus A. Horwitz
Gunter Harth
Paul C. Zamecnik
Original Assignee
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of California filed Critical The Regents Of The University Of California
Priority to US10/168,244 priority Critical patent/US20040033972A1/en
Priority to AU24446/01A priority patent/AU2444601A/en
Publication of WO2001046473A1 publication Critical patent/WO2001046473A1/fr
Priority to PCT/US2002/015963 priority patent/WO2002094848A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y205/00—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5)
    • C12Y205/01—Transferases transferring alkyl or aryl groups, other than methyl groups (2.5) transferring alkyl or aryl groups, other than methyl groups (2.5.1)
    • C12Y205/01019—3-Phosphoshikimate 1-carboxyvinyltransferase (2.5.1.19), i.e. 5-enolpyruvylshikimate-3-phosphate synthase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y603/00—Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/01—Acid-ammonia (or amine)ligases (amide synthases)(6.3.1)
    • C12Y603/01002—Glutamate-ammonia ligase (6.3.1.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C

Definitions

  • the present invention relates to the use of antisense polynucleotides as prophylactic and therapeutic agents in the treatment oi Mycobacterium tuberculosis infection.
  • Tuberculosis has been a major health problem for most of recorded history and Mycobacterium tuberculosis remains one of the world's most significant pathogens. Responsible for millions of new cases of tuberculosis annually (see e.g. Pablo-Mendez et al., (1998) NewEngl. J. Med. 338, 1641-1649), it is the leading cause of death from a single infectious agent. While the incidence of the disease declined in parallel with advancing standards of living since at least the mid-nineteenth century, in spite of the efforts of numerous health organizations worldwide, the eradication of tuberculosis has never been achieved, nor is iiiiminent.
  • TB is acquired by the respiratory route; actively infected individuals spread this infection efficiently by coughing or sneezing "droplet nuclei" which contain viable bacilli.
  • Overcrowded living conditions and shared air spaces are especially conducive to the spread of TB, underlying the increase in instances that have been observed in the U.S. in prison inmates and among the homeless in larger cities.
  • the invention disclosed herein comprises compounds and methods for treating or preventing Mycobacterium tuberculosis infection (tuberculosis) using antisense compounds such as antisense polynucleotides.
  • the invention comprises a method for treating or preventing Mycobacterium tuberculosis infection using antisense or other site-specific polynucleotides directed against the mRNA or DNA of the gene encoding M. tuberculosis glutamine synthetase.
  • An illustrative embodiment consists of a method of inhibiting Mycobacterium tuberculosis glutamine synthetase protein expression comprising contacting a Mycobacterium tuberculosis bacterium with an effective amount of an antisense compound comprising an antisense polynucleotide that hybridizes to a Mycobacterium tuberculous glutamine synthetase polynucleotide, wherein the antisense polynucleotide hybridizes to a region of the Mycobacterium tuberculosis glutamine synthetase polynucleotide encoding the glutamine synthetase protein, thereby inhibiting Mycobacterium tuberculosis glutamine synthetase protein expression.
  • the polynucleotide is selected from the group consisting of 5'-GAC GTC GTC GGG CGT CTT-3' (SEQ ID NO: 18), 5'-CAT GCC GGA CCC GTT GTC GCC-3' (SEQ ID NO: 19) and 5'-CCA CAG CGA CTG ATG ACA GTG CAT-3' (SEQ ID NO: 20).
  • the invention comprises a method for treating or preventing Mycobacterium tuberculosis infection using antisense or other site-specific polynucleotides directed against the mRNA or DNA of the M. tuberculosis aroA gene.
  • the invention comprises a method for treating or preventing Mycobacterium tubercidosis infection using antisense or other site-specific polynucleotides directed against the mRNA or DNA of the M. tuberculosis ask gene.
  • the invention comprises a method for treating or preventing Mycobacterium tuberculosis infection using antisense or other site-specific polynucleotides directed against the mRNA or DNA of genes encoding the M. tuberculosis 30/32 kDa (Antigen 85) extracellular protein complex.
  • the antisense polynucleotide is relatively devoid of secondary structures.
  • the polynucleotide is a phosphorothioate modified antisense polynucleotide.
  • the method comprises contacting the Mycobacterium tuberculosis with both a polynucleotide as well as an effective amount of an antibiotic capable of inhibiting the proliferation of Mycobacterium tuberculosis such as rifampin, isoniazid, amikacin, ethambutol and polymyxin B nonapeptide.
  • multiple polynucleotides targeting different regions of one or more genes and/or gene transcripts are used to treat or prevent Mycobacterium tuberculosis infection.
  • Yet another embodiment of the method consists of a process for producing an antisense compound that inhibits the expression of a Mycobacterium tuberculosis gene (e.g. glutamine synthetase) by synthesizing a antisense polynucleotide of about 15 to about 50 nucleobases in length capable of hybridizing to a portion of polynucleotide encoding a Mycobacterium tuberculosis glutamine synthetase protein and then comparing the levels of Mycobacterium tuberculosis glutamine synthetase protein expression in a Mycobacterium tuberculosis culture exposed to an effective amount of the antisense polynucleotide levels in a control culture.
  • a related embodiment consists of an antisense polynucleotide produced according to this process.
  • PS-ODNs phosphorothioate modified antisense polynucleotides
  • Treatment of virulent M. tuberculosis with 10 ⁇ M antisense PS-ODNs reduced glutamine synthetase activity and expression by 25-50% depending upon whether one, two, or three different PS-ODNs were used and the PS-ODN's specific target site on the mRNA.
  • tuberculosis glutamine synthetase selectively inhibited the recombinant enzyme but not the endogenous enzyme for which the mRNA transcript was mismatched by 2-4 nucleotides.
  • Treatment of M. tuberculosis with the antisense PS-ODNs also reduced the amount of poly-L-glutamate/glutamine in the cell wall by 24%.
  • Treatment with antisense PS-ODNs reduced M. tuberculosis growth by 0.7 logs (1 PS-ODN) to 1.25 logs (3 PS-ODNs) but had no effect on the growth of M. smegmatis, which does not export glutamine synthetase nor possess the poly-L-glutamate/glutamine cell wall structure.
  • the experiments indicate that the antisense PS-ODNs enter the cytoplasm of M. tuberculosis and bind to their cognate targets.
  • the disclosure provided herein demonstrates the feasibility of using antisense
  • Figures 1A-1B show the inhibition of M. tuberculosis Erdman glutamine synthetase activity by antisense PS-ODNs.
  • Figure IA shows the inhibition of cellular glutamine synthetase activity of M. tuberculosis Erdman by antisense PS-ODNs.
  • Figure IB shows the inhibition of extracellular glutamine synthetase activity of M. tuberculosis Erdman by antisense PS-ODNs.
  • Duplicate M. tuberculosis Erdman cultures were grown for two weeks in 1 - 2 ml 7H9 medium alone and thereafter in the absence or the presence of antisense PS-ODNs, individually or combined, at concentrations of 10 ⁇ M.
  • Figures 2A-2D show the inhibition of glutamine synthetase activity in M. smegmatis l-2c wildtype and its recombinant isotype expressing the M. tuberculosis glutamine synthetase.
  • Figure 2A shows die inhibition of cellular glutamine synthetase activity of M. smegmatis l-2c wildtype by antisense PS-ODNs.
  • Figure 2B shows the inhibition of extracellular glutamine synthetase activity of M. smegmatis l-2c wildtype by antisense PS-ODNs.
  • Figure 2C shows the inhibition of cellular glutamine synthetase activity of M. smegmatis l-2c + rM.tb.
  • FIG. 2D shows the inhibition of extracellular glutamine synthetase activity of M. smegmatis l-2c + rM.tb. GS by antisense PS-ODNs.
  • Duplicate M. smegmatis cultures were grown for two days in 1 - 2 ml 7H9 medium alone and thereafter in the absence or the presence of antisense PS- ODNs, individually or combined, at concentrations of 10 ⁇ M. At each time point indicated, cultures were harvested and analyzed for glutamine synthetase activity by the transfer assay as described (Harth et al., (1994) Proc. Natl. Acad. Sci. USA 91, 9342-9346).
  • the cellular enzyme activity of the recombinant strain is a mixture of two enzyme activities - the endogenous glutamine synthetase (60%) and recombinant M. tuberculosis glutamine synthetase (40%).
  • the extracellular enzyme activity of the recombinant strain is almost exclusively M. tuberculosis glutamine synthetase ( ⁇ 99%). All data points had a standard deviation of ⁇ 15%.
  • Figures 3A-3B show the inhibition of cell proliferation of M. tuberculosis Erdman and M. smegmatis l-2c wildtype and recombinant strain by antisense PS-ODNs.
  • Figure 3A shows the inhibition of cell proliferation of M. tuberculosis Erdman broth cultures by antisense PS-ODNs.
  • Figure 3B shows the inhibition of cell proliferation of M. smegmatis l-2c +/- rM.tb. GS broth cultures by antisense PS-ODNs.
  • Duplicate bacterial cultures were grown for six weeks (M. tuberculosis) or six days (M.
  • smegmatis in 1 - 2 ml 7H9 medium in the presence of the antisense PS-ODNs, individually or combined, at concentrations of 10 ⁇ M.
  • cultures were harvested, washed, serially diluted, and plated on 7H11 agar medium.
  • Viable bacteria were enumerated after an incubation period of 2 weeks (M. tuberculosis) or 3 days (M. smegmatis). Standard deviations varied between 15 - 20%. There were no significant differences in growth of M. smegmatis 1-2c in the presence or absence of PS-ODNs.
  • Figures 4A-4C show the inhibition of cell proliferation of M. tuberculosis Erdman by antisense PS-ODNs in the presence of various concentrations of ethambutol or polymyxin B nonapeptide.
  • Figure 4A shows the inhibition of cell proliferation of M. tuberculosis Erdman broth cultures by antisense PS-ODNs in the presence of various concentrations of ethambutol (EMB).
  • Figure 4B shows the inhibition of cell proliferation of M. tuberculous Erdman broth cultures by antisense PS-ODNs in the presence of various concentrations of polymyxin B nonapeptide (PMBN).
  • Figure 4C shows the inhibition of cell proliferation of M.
  • EMB ethambutol
  • PMBN polymyxin B nonapeptide
  • EMB ethambutol
  • PMBN polymyxin B nonapeptide
  • Viable bacteria were enumerated after an incubation period of 2 weeks (M. tuberculosis) or 3 days (M. smegmatis). Standard deviations varied between 15 - 20%. Values' for single PS- ODNs were combined to yield one dashed line; the range of values for single PS-ODNs is indicated by the broad, solid vertical bar.
  • Figure 5 shows a graph of Val 23 with and without Ethambutol (ETH) (5 ⁇ g /ml).
  • Figure 6 shows a graph of Val 24 with and without Ethambutol (ETH) (5 ⁇ g /ml).
  • Figure 7 shows a graph of Val 25 with and without Ethambutol (ETH) (5 ⁇ g
  • Figure 8 shows a graph of Val 26 with and without Ethambutol (ETH) (5 ⁇ g /ml),
  • Figure 9 shows a graph of Val 33 with and without Ethambutol (ETH) (5 ⁇ g /ml),
  • Figure 10 shows a graph of Val 34 with and without Ethambutol (ETH) (5 ⁇ g /ml).
  • Figure 11 shows a graph of Val 41 with and without Ethambutol (ETH) (5 ⁇ g /ml).
  • Figure 12 shows a graph of ML10 with and without Ethambutol (ETH) (5 ⁇ g
  • Figure 13 shows the inhibition of cell proliferation of M. tuberculous Erdman broth cultures by modified antisense PS-ODN 269-275 at 10 ⁇ M. This Figure shows that 269-275-DAO was more effective at 10 ⁇ M than PS-ODN 269-275 at inhibiting the growth of M. tuberculosis.
  • the control ODN yielded no inhibition of growth, i.e. it was equivalent to no ODN being added.
  • Figure 14 shows the inhibition of cell proliferation of M. smegmatis l-2c +/- rM.tb. GS broth cultures by modified antisense PS-ODN 269-275 at 10 ⁇ M. This Figure shows that 269-275-DAO does not inhibit M. smegmatis.
  • Figure 15 shows the inhibition of cell proliferation of M. tuberculosis Erdman broth cultures by modified antisense PS-ODN 269-275 at 10 ⁇ M. This Figure shows that only 5N-269-275 PS-ODN was more effective than PS-ODN 269-275 and that there was a trend toward greater inhibition with higher "N" groups. (5N> 4N>
  • Figures 16A-16E show the modified ODNs (derivatives with 5', 3' and 5'-3' amino linkers) as described and evaluated in Example 9.
  • kits and reagents are generally carried out in accordance with manufacturer defined protocols and/ or parameters unless otherwise noted.
  • a variety of art accepted definitions and methods for manipulating, evaluating and utilizing antisense compounds are well known in the art and are widely used as a standard practice in the field of biotechnology. Such common terms and practices are provided, for example in U.S. Patent No. 6,140,126, which is incorporated herein by reference and which, recites a variety of the common terms and methodologies illustrated below.
  • the present invention employs oligomeric antisense compounds, particularly polynucleotides for use in modulating the expression and function of nucleic acid molecules encoding M.
  • tuberculosis genes such as glnA, aroA, ask, groES, and the 30/32 kDa extracellular protein complex [30, 32A, 32B extracellular proteins (Antigens 85B, 85A, and 85C respectively)] by modulating the amount of protein produced from these M. tuberculosis genes.
  • embodiments of a single gene are used (for example the glutamine synthetase gene) to illustrate typical embodiments of the invention that apply to all of the methods and compositions for modulating glutamine synthetase, aroA, ask, groES and the 30/32 kDa extracellular protein complex genes.
  • Modulating the function of M. tuberculosis genes such as glutamine synthetase is accomplished by providing antisense compounds which specifically hybridize with one or more nucleic acids encoding glutamine synthetase.
  • target nucleic acid and “polynucleotide encoding glutamine synthetase” encompass DNA encoding glutamine synthetase, RNA (including pre-mRNA and mRNA) transcribed from such DNA, and also cDNA derived from such RNA. The specific hybridization of an oligomeric compound with its target nucleic acid interferes with the normal function of the nucleic acid.
  • RNA to be interfered with include all vital functions such as, for example, translocation of the RNA to the site of protein translation, translation of protein from the RNA, splicing of the RNA to yield one or more mRNA species, and catalytic activity which may be engaged in or facilitated by the RNA.
  • the overall effect of such interference with target nucleic acid function is modulation of the expression of a M. tuberculosis gene such as glutamine synthetase.
  • modulation means either an increase (stimulation) or a decrease (inhibition) in the expression of a gene.
  • inhibition is the preferred form of modulation of gene expression and mRNA is a preferred target.
  • Targeting an antisense compound to a particular nucleic acid is a multistep process. The process usually begins with the identification of a nucleic acid sequence whose function is to be modulated.
  • the target is a nucleic acid molecule encoding M. tuberculosis proteins such as glutamine synthetase.
  • the targeting process also includes determination of a site or sites within this gene for the antisense interaction to occur such that the desired effect, e.g., detection or modulation of expression of the protein, will result.
  • a preferred site is the region within the open reading frame (ORF) of the gene.
  • the translation initiation codon is typically 5'-AUG (in transcribed mRNA molecules; 5'-ATG in the corresponding DNA molecule), the translation initiation codon is also referred to as the "AUG codon," the "start codon” or the "AUG start codon”.
  • a minority of genes have a translation initiation codon having the RNA sequence 5'-GUG or 5'-UUG,and 5'-AUA, 5'-ACG and 5'-CUG have been shown to function in vivo.
  • translation initiation codon and “start codon” can encompass many codon sequences, even though the initiator amino acid in each instance is typically methionine (in eukaryotes) or N-formylmethionine (in prokaryotes). It is also known in the art that eukaryotic and prokaryotic genes may have two or more alternative start codons, any one of which may be preferentially utilized for translation initiation in a particular cell type or tissue, or under a particular set of conditions.
  • start codon and “translation initiation codon” refer to the codon or codons that are used in vivo to initiate translation of an mRNA molecule transcribed from a gene encoding glutamine synthetase, regardless of the sequence(s) of such codons.
  • a translation termination codon (or "stop codon”) of a gene may have one of t tee sequences, i.e., 5'-UAA, 5'-UAG and 5'-UGA (the corresponding DNA sequences are 5'-TAA, 5'-TAG and 5'-TGA, respectively).
  • start codon region and “translation initiation codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation initiation codon.
  • stop codon region and “translation termination codon region” refer to a portion of such an mRNA or gene that encompasses from about 25 to about 50 contiguous nucleotides in either direction (i.e., 5' or 3') from a translation termination codon.
  • hybridization means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleoside or nucleotide bases.
  • adenine and thymine are complementary nucleobases which pair through the formation of hydrogen bonds.
  • “Complementary,” as used herein, refers to the capacity for precise base pairing between two nucleotides.
  • a nucleotide at a certain position of a polynucleotide is capable of hydrogen bonding with a nucleotide at the same position of a DNA or RNA molecule
  • the polynucleotide and the DNA or RNA are considered to be complementary to each other at that position.
  • the polynucleotide and the DNA or RNA are complementary to each other when a sufficient number of corresponding positions in each molecule are occupied by nucleotides which can hydrogen bond with each other.
  • “specifically hybridizable” and “complementary” are terms which are used to indicate a sufficient degree of complementarity or precise pairing such that stable and specific binding occurs between the polynucleotide and the DNA or RNA target.
  • an antisense compound need not be 100% complementary to that of its target nucleic acid to be specifically hybridizable.
  • An antisense compound is specifically hybridizable when binding of the compound to the target DNA or RNA molecule interferes with the normal function of the target DNA or RNA to cause a loss of utility, and there is a sufficient degree of complementarity to avoid non-specific binding of the antisense compound to non-target sequences under conditions in which specific binding is desired, i.e., under physiological conditions in the case of in vivo assays or therapeutic treatment, or in the case of in vitro assays, under conditions in which the assays are performed.
  • Antisense compounds are commonly used as research reagents and diagnostics. For example, antisense polynucleotides, which are able to inhibit gene expression with extraordinar specificity, are often used by those of ordinary skill to elucidate the function of particular genes. In the context of pathogenic organisms that have developed resistance to an existing antibiotic armamentarium (such as Mycobacterium tuberculous), an elucidation of the function of particular genes (e.g. glutamine synthetase) is crucial for the development of the next generation of antibiotic therapeutics. Antisense modulation of protein activity has therefore been harnessed for research involving the treatment of disease. Antisense compounds are also used in other contexts, for example to distinguish between functions of various members of a biological pathway.
  • antisense compounds such as those disclosed herein can be used in a number of in vitro contexts, for example to prevent the growth of bacteria in mediums practitioners wish to keep free of contamination.
  • the specificity and sensitivity of antisense is also harnessed by those of skill in the art for therapeutic uses.
  • Antisense polynucleotides have been employed as therapeutic moieties in the treatment of disease states in animals and man. Antisense polynucleotides have been safely and effectively administered to humans and numerous clinical trials are presently underway. It is thus established that polynucleotides can be useful therapeutic modalities that can be configured to be useful in treatment regimes for treatment of cells, tissues and animals, especially humans (see e.g. Barker et al., (1996) Proc. Natl.
  • polynucleotide refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or mimetics thereof.
  • RNA ribonucleic acid
  • DNA deoxyribonucleic acid
  • polynucleotides composed of naturally-occurring nucleobases, sugars and covalent internucleoside (backbone) linkages as well as polynucleotides having non-naturally-occurring portions which function similarly.
  • backbone internucleoside
  • modified or substituted polynucleotides are often preferred over native forms because of desirable properties such as, for example, enhanced cellular uptake, enhanced affinity for nucleic acid target and increased stability in the presence of nucleases.
  • antisense polynucleotides are a preferred form of antisense compound
  • the present invention comprehends other oligomeric antisense compounds, including but not limited to polynucleotide mimetics such as are described below.
  • the antisense compounds in accordance with this invention preferably comprise from about 8 to about 30 nucleobases.
  • Particularly preferred are antisense polynucleotides comprising from about 8 to about 30 nucleobases (i.e. from about 8 to about 30 linked nucleosides).
  • a nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base.
  • Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside.
  • the phosphate group can be linked to either the 2', 3' or 5' hydroxyl moiety of the sugar.
  • the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn the respective ends of this linear polymeric structure can be further joined to form a circular structure, however, open linear structures are generally preferred.
  • the phosphate groups are commonly referred to as forming the internucleoside backbone of the polynucleotide.
  • the normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.
  • polynucleotides containing modified backbones or non-natural internucleoside linkages include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone.
  • modified polynucleotides that do not have a phosphorus atom in their internucleoside backbone can also be considered to be oligonucleosides.
  • Preferred modified polynucleotide backbones include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'- amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein the adjacent pairs of nucleoside units are linked 3'-5' to 5'-3' or 2'-5' to 5'-2'.
  • Preferred modified polynucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages.
  • oligonucleosides include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and tliioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; alkene containing backbones; sulfamate backbones; n etiiyleneirnino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH 2 component parts.
  • Representative United States patents that teach the preparation of the above oligonucleosides include, but are not limited to, U.S. Pat. Nos.: 5,034,506; 5,166,315;
  • both the sugar and the internucleoside linkage, i.e., the backbone, of the nucleotide units are replaced with novel groups.
  • the base units are maintained for hybridization with an appropriate nucleic acid target compound.
  • One such oligomeric compound, a polynucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA).
  • PNA peptide nucleic acid
  • the sugar-backbone of a polynucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone.
  • nucleobases are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.
  • Representative United States patents that teach the preparation of PNA compounds include, but are not limited to, U.S. Pat. Nos.: 5,539,082; 5,714,331; and 5,719,262, each of which is herein incorporated by reference. Further teaching of PNA compounds can be found in Nielsen et al, (Science, 1991, 254, 1497-1500).
  • Most preferred embodiments of the invention are polynucleotides with phosphorothioate backbones and oligonucleosides with heteroatom backbones, and in particular -CH 2 -NH-0 ⁇ CH 2 -, -CH 2 ⁇ N(CH 3 )-0-CH 2 -
  • Modified polynucleotides may also contain one or more substituted sugar moieties.
  • Preferred polynucleotides comprise one of the following at the 2' position: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted Ci to C I Q alkyl or C 2 to CIQ alkenyl and alkynyl.
  • n and m are from 1 to about 10.
  • polynucleotides comprise one of the following at the 2' position: Ci to C10 lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH3, OCN, Cl, Br, CN, CF 3 , OCF3, SOCH3, S0 2 CH3, ONO2, N0 2 , N 3 , NH 2 , heterocycloalkyl, heterocycloalkaryl, a___inoall_ylamino, polyall_ylam_no, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of a polynucleotide, or a group for improving the pharmacodynamic properties of a polynucleotide, and other substituents having similar properties.
  • a preferred modification includes 2'-methoxyethoxy (2'-0— CH 2 CH 2 -OCH3, also known as 2'-O-(2- methoxyethyl) or 2'-MOE) (Martin et al., Helv. Chim. Acta, 1995, 78, 486-504) Le., an alkoxyalkoxy group.
  • modifications include 2' -methoxy (2'-0— CH3), 2'-aminopropoxy (2'-OCH 2 CH 2 CH 2 NH 2 ) and 2'-fluoro (2'-F). Similar modifications may also be made at other positions on the polynucleotide, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked polynucleotides and the 5' position of the 5' terminal nucleotide. Polynucleotides may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar. Representative United States patents that teach the preparation of such modified sugar structures include, but are not limited to, U.S. Pat.
  • Polynucleotides may also include nucleobase (often referred to in the art simply as “base”) modifications or substitutions.
  • nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U).
  • Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2- thiouracil, 2-tHothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-fhiouracil, 8- halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-tri_luoromethyl and
  • nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in The Concise Encyclopedia Of Polymer Science And Engineering, I ⁇ _rosc__witz, J. I., ed. John Wiley & Sons, 1990, 858-859, those disclosed by Englisch et al., (Angewandte Chemie, IE, 1991, 30, 613), and those disclosed by Sanghvi, Y. S., (Antisense Research and Applications, 15, 289-302), and Crooke, S. T. and Lebleu, B., ed., (CRC Press, 1993). Certain of these nucleobases are particularly useful for increasing the binding affinity of the oligomeric compounds of the invention.
  • 5-substituted pyrimidines include 5-substituted pyrimidines, 6- azapyrimidines and N-2, N-6 and 0-6 substituted purines, including 2- aminopropyladenine, 5-propynyluracil and 5-propynylcytosine.
  • 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2°C. (Sanghvi, Y. S., Crooke, S. T. and Lebleu, B., eds., Antisense Research and Applications 1993, 276-278) and are presently preferred base substitutions, even more particularly when combined with 2'-0-methoxyethyl sugar modifications.
  • Another modification of the polynucleotides of the invention involves chemically linking to the polynucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the polynucleotide.
  • moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem. Let., 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., Ann.
  • Acids Res., 1990, 18, 3777-3783 a polyamine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett, 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim. Biophys. Acta, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl- oxycholesterol moiety (Crooke et al, J. Pharmacol. Exp. Ther., 1996, 277, 923-937.
  • the present invention also includes antisense compounds which are chimeric compounds.
  • "Chimeric” antisense compounds or “chimeras, " in the context of this invention, are antisense compounds, particularly polynucleotides, which contain two or more chemically distinct regions, each made up of at least one monomer unit, i.e., a nucleotide in the case of a polynucleotide compound.
  • polynucleotides typically contain at least one region wherein the polynucleotide is modified so as to confer upon the polynucleotide increased resistance to nuclease degradation, increased cellular uptake, and/ or increased binding affinity for the target nucleic acid.
  • An additional region of the polynucleotide may serve as a substrate for enzymes capable of cleaving RN ADNA or RNA:RNA hybrids. Consequently, comparable results can often be obtained with shorter polynucleotides when chimeric polynucleotides are used, compared to phosphorothioate deoxypolynucleotides hybridizing to the same target region.
  • Chimeric antisense compounds of the invention may be formed as composite structures of two or more polynucleotides, modified polynucleotides, oligonucleosides and/ or polynucleotide mimetics as described above. Such compounds have also been referred to in the art as hybrids or gapmers. Representative United States patents that teach the preparation of such hybrid structures include, but are not limited to, U.S. Pat.
  • the antisense compounds used in accordance with this invention may be conveniently and routinely made through the well-known technique of solid phase synthesis.
  • Equipment for such synthesis is sold by several vendors including, for example, Applied Biosystems (Foster City, Calif.). Any other means for such synthesis known in the art may additionally or alternatively be employed. It is well known to use similar techniques to prepare polynucleotides such as the phosphorothioates and alkylated derivatives.
  • the antisense compounds of the invention are synthesized in vitro and do not include antisense compositions of biological origin, or genetic vector constructs designed to direct the in vivo synthesis of antisense molecules.
  • the compounds of the invention may also be admixed, encapsulated, conjugated or otherwise associated with other molecules, molecule structures or mixtures of compounds, as for example, liposomes, receptor targeted molecules, oral, rectal, topical or other formulations, for assisting in uptake, distribution and/or absorption.
  • Representative United States patents that teach the preparation of such uptake, distribution and/ or absorption assisting formulations include, but are not limited to, U.S. Pat.
  • the antisense compounds of the invention encompass any pharmaceutically acceptable salts, esters, or salts of such esters, or any other compound which, upon administration to an animal including a human, is capable of providing (directly or indirectly) the biologically active metabolite or residue thereof. Accordingly, for example, the disclosure is also drawn to prodrugs and pharmaceutically acceptable salts of the compounds of the invention, pharmaceutically acceptable salts of such prodrugs, and other bioequivalents.
  • prodrug indicates a therapeutic agent that is prepared in an inactive form that is converted to an active form (i.e., drug) within the body or cells thereof by the action of endogenous enzymes or other chemicals and/ or conditions.
  • prodrug versions of the polynucleotides of the invention are prepared as SATE [(S- acetyl-2-thioethyl)phosphate] derivatives according to the methods disclosed in WO 93/24510 to Gosselin et al., published Dec. 9, 1993 or in WO 94/26764 to Imbach et al.
  • pharmaceutically acceptable salts refers to physiologically and pharmaceutically acceptable salts of the compounds of the invention: i.e., salts that retain the desired biological activity of the parent compound and do not impart undesired toxicological effects thereto.
  • Pharmaceutically acceptable base addition salts are formed with metals or amines, such as alkali and alkaline earth metals or organic amines.
  • metals used as cations are sodium, potassium, magnesium, calcium, and the like.
  • suitable amines are N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, dicyclohexylamine, ethylenediamine, N-memylglucamine, and procaine (see, for example, Berge et al. J. of Pharma Sci., 1977, 66, 1-19).
  • the base addition salts of said acidic compounds are prepared by contacting the free acid form with a sufficient amount of the desired base to produce the salt in the conventional manner.
  • the free acid form may be regenerated by contacting the salt form with an acid and isolating the free acid in the conventional manner.
  • the free acid forms differ from their respective salt forms somewhat in certain physical properties such as solubility in polar solvents, but otherwise the salts are equivalent to their respective free acid for purposes of the present invention.
  • a "pharmaceutical addition salt” includes a pharmaceutically acceptable salt of an acid form of one of the components . of the compositions of the invention. These include organic or inorganic acid salts of the amines.
  • Preferred acid salts are the hydrochlorides, acetates, salicylates, nitrates and phosphates.
  • Suitable pharmaceutically acceptable salts include basic salts of a variety of inorganic and organic acids, such as, for example, with inorganic acids, such as for example hydrochloric acid, hydrobromic acid, sulfuric acid or phosphoric acid; with organic carboxylic, sulfonic, sulfo or phospho acids or N- substituted sulfamic acids, for example acetic acid, propionic acid, glycolic acid, succinic acid, maleic acid, hydroxymaleic acid, methylmaleic acid, fumaric acid, malic acid, tartaric acid, lactic acid, oxalic acid, gluconic acid, glucaric acid, glucuronic acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, salicylic acid, 4-aminosalicylic acid, 2- phenoxybenzoic acid, 2-acetoxybenzoic acid, embonic acid, nicotinic acid or isonicotinic acid
  • Pharmaceutically acceptable salts of compounds may also be prepared with a pharmaceutically acceptable cation.
  • Suitable pharmaceutically acceptable cations are well known to those skilled in the art and include alkaline, alkaline earth, ammonium and quaternary ammonium cations. Carbonates or hydrogen carbonates are also possible.
  • salts formed with cations such as sodium, potassium, ammonium, magnesium, calcium, polyamines such as spermine and spermidine, etc.
  • acid addition salts formed with inorganic acids for example hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, nitric acid and the like
  • salts formed with organic acids such as, for example, acetic acid, oxalic acid, tartatic acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, palmitic acid, alginic acid, polyglutamic acid, naphthalenesulfonic acid, methanesulfonic acid, p-toluenesulfonic acid, naphthalenedisulfonic acid, polygalacturonic acid, and
  • the antisense compounds of the present invention can be utilized for diagnostics, therapeutics, prophylaxis and as research reagents and kits.
  • an animal preferably a human, suspected of having a disease or disorder associated with Mycobacterium tuberculosis infection which can be treated by modulating the expression of a Mycobacterium tuberculosis gene such as glutamine syntiietase is treated by a_______minded antisense compounds in accordance with this invention.
  • the compounds of the invention can be utilized in pharmaceutical compositions by adding an effective amount of an antisense compound to a suitable pharmaceutically acceptable diluent or carrier.
  • Use of the antisense compounds and methods of the invention may also be useful prophylactically, e.g., to prevent or delay infection, for example.
  • the antisense compounds of the invention are useful for research and diagnostics, because these compounds hybridize to nucleic acids encoding, for example, glutamine synthetase, enabling sandwich and other assays to easily be constructed to exploit this fact.
  • Hybridization of the antisense polynucleotides of the invention with a nucleic acid encoding glutamine synthetase can be detected by means known in the art. Such means may include conjugation of an enzyme to the polynucleotide, radiolabelling of the polynucleotide or any other suitable detection means. Kits using such detection means for detecting the level of glutamine synthetase in a sample may also be prepared.
  • the present invention also includes pharmaceutical compositions and formulations which include the antisense compounds of the invention.
  • the pharmaceutical compositions of the present invention may be act inistered in a number of ways depending upon whether local or systemic treatment is desired and upon the area to be treated. Aclministration may be topical (including ophthalmic and to mucous membranes including vaginal and rectal delivery), pulmonary, e.g., by inhalation or insufflation of powders or aerosols, including by nebulizer; intratracheal, intranasal, epidermal and transdermal), oral or parenteral.
  • Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion; or intracranial, e.g., intrathecal or intraventricular, a ⁇ _m_nistration.
  • Polynucleotides with at least one 2'-0-methoxyethyl modification are believed to be particularly useful for oral administration.
  • compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
  • Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be necessary or desirable.
  • Coated condoms, gloves and the like may also be useful.
  • compositions and formulations for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets or tablets. Thickeners, flavoring agents, diluents, emulsifiers, dispersing aids or binders may be desirable.
  • Compositions and formulations for parenteral, intrathecal or intraventricular a ⁇ _____i__istration may include sterile aqueous solutions which may also contain buffers, diluents and other suitable additives such as, but not limited to, penetration enhancers, carrier compounds and other pharmaceutically acceptable carriers or excipients.
  • compositions and/or formulations comprising the polynucleotides of the present invention may also include penetration enhancers in order to enhance the alimentary delivery of the polynucleotides.
  • Penetration enhancers may be classified as belonging to one of five broad categories, i.e., fatty acids, bile salts, chelating agents, surfactants and non-surfactants (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, 8, 91-192; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33).
  • One or more penetration enhancers from one or more of these broad categories may be included.
  • fatty acids and their derivatives which act as penetration enhancers include, for example, oleic acid, lauric acid, capric acid, myristic acid, palmitic acid, stearic acid, linoleic acid, linolenic acid, dicaprate, tricaprate, recinleate, monoolein (a.k.a.
  • fatty acids 1- monooleoyl-rac-glycerol), dilaurin, caprylic acid, arachidonic acid, glyceryl 1- monocaprate, l-dodecylazacycloheptan-2-one, acylcarnitines, acylcholines, mono- and di- glycerides and physiologically acceptable salts thereof (i.e., oleate, laurate, caprate, myristate, palmitate, stearate, linoleate, etc.) (Lee et al., Critical Reviews in Therapeutic Drug Carrier Systems, 1991, 8, 91-192; Muranishi, Critical Reviews in Therapeutic Drug Carrier Systems, 1990, 7, 1-33; El-Hariri et al., J. Pharm. Pharmacol., 1992, 44, 651-654).
  • examples of some presently preferred fatty acids are sodium caprate and sodium laurate, used singly or in combination at concentrations of 0.5 to 5%.
  • antisense polynucleotides to modulate the expression and function of M. tuberculosis genes including glutamine synthetase, aroA, ask, groES and the genes of the Antigen 85 family or complex.
  • PS-ODNs modified antisense ODNs, in which all internucleoside linkages are phosphorothioates (PS-ODNs), PS-ODNs substantially inhibit the expression of M.
  • tuberculosis glutamine synthetase glutamine synthetase
  • the reduction in enzyme activity correlates with a reduction in the amount of the poly-L- glutamate/glutamine structure in the mycobacterial cell wall and with substantial inhibition of bacterial replication.
  • tuberculosis and the expression of its glutamine synthetase they had no effect on M. smegmatis growth or the expression of its closely related glutamine synthetase. Moreover, control PS-ODNs had no effect on M. tuberculosis growth or glutamine synthetase expression.
  • PS-ODNs phosphorothioate modified
  • tuberculosis without employing strategies necessary to overcome the problems observed with M. smegmatis was therefore surprising and unexpected. Moreover a comparison of the data presented herein with previously reports that oligomers complementary to M. smegmatis genes other than those targeted to the M. smegmatis ask-asd operon were ineffective provides evidence that M. smegmatis provides a limited comparative model for evaluating antisense molecules in M. tuberculosis (Rapaport et al., P.N.A.S. 93: 709-713 (1996)).
  • tuberculous proteins as shown in the Examples below is consistent with the observation that naturally occurring antisense polynucleotides have been found to function in prokaryotic cells as natural modulators of some proteins (see e.g. Pestka, S. Ann NY Acad Sci 660: 251-262 (1992; Simons, R. Gene 72(1-2): 35-44 (1988).
  • antisense polynucleotides directed against the mRNA of the gene encoding M. tuberculosis glutamine synthetase could inhibit the growth of this pathogen.
  • three different PS-ODNs directed against the mRNlA of M. tuberculosis glutamine synthetase substantially inhibit the growth of this pathogen.
  • the inhibitory capacity was related to the propensity of the polynucleotide to remain in a linear configuration, i.e. the polynucleotides with the stronger propensity to remain in a linear configuration inhibited more effectively.
  • This PS-ODN was the only one of the four that was complementary only to the coding region of the gene; the others were complementary exclusively or partly to upstream non-coding regions.
  • the one PS-ODN that was inhibitory for M. tuberculosis growth also was one of two PS- ODNs with a strong propensity to remain linear.
  • antisense polynucleotides directed against the mRNA or DNA of the M. tuberculosis ask gene could inhibit the growth of this pathogen.
  • two PS-ODNs directed against the mRNA or DNA of the M. tuberculosis ask gene substantially inhibit the growth of this pathogen.
  • PS-ODNs were a 27-mer and the other was a 36-mer, both directed against the same target site (i.e. one was a 9-mer extension of the other).
  • the longer PS-ODN inhibited growth better than the shorter PS-ODN in the one experiment in which the two PS-ODNs were tested.
  • antisense polynucleotides directed against the mRNA or DNA of the genes encoding the M. tuberculosis 30/32 kDa (Antigen 85) extracellular protein complex [30, 32A, 32B extracellular proteins (Antigens 85B, 85A, and 85C respectively)] could inhibit the growth of this pathogen.
  • PS-ODN directed against each mRNA or DNA of the genes encoding the M. tuberculosis 30/32 kDa (Antigen 85) extracellular protein complex partially inhibits the growth of this pathogen.
  • the PS-ODN was fully complementary to the mRNA encoding the 32A protein and mismatched by one nucleotide each with the mRNAs encoding the 30 or 32B proteins.
  • the data presented herein which shows that antisense polynucleotides can be used to inhibit the expression of a variety of different M. tuberculosis genes provides evidence that neither the structure of the prokaryotic M. tuberculosis cell wall nor the M.
  • tuberculosis cellular machinery provide significant barriers to the use of antisense polynucleotides to modulate the expression of M. tuberculosis genes. Instead, the data presented herein provides evidence that the physiology of this organism is particularly amenable to the use antisense polynucleotides for modulating protein expression in the manner described herein.
  • WO9803533A1, WO9950277A1, WO9604788A1, WO9500638A3, WO9104753A1 and WO9901579A1 all which are incorporated herein by reference.
  • the invention disclosed herein provides not just new antibiotics to treat both drug resistant and drug sensitive strains but a whole new approach to treatment of M. tuberculosis infection.
  • the technology allows the generation of polynucleotides directed against thousands of different mRNA or DNA targets.
  • the polynucleotides could be used in combination, as we have found that combinations of different polynucleotides are more potent than individual ones. Moreover, provided they are sufficiently long to hybridize with the target nucleic acid, the polynucleotides could have one or several mismatches with the target nucleic acid and still be efficacious; hence, they would tolerate some genetic diversity among strains and some mutations of the target nucleic acid. Moreover, modifications of internucleoside phosphates other than phosphorothioates may be used to inhibit the replication of M. tuberculosis.
  • tuberculosis pathogenesis see e.g. Harth et al., (1994) Proc. Natl. Acad. Sci. USA 91, 9342-9346; Harth et al, (1997) /. Biol. Chem. 272, 22728-22735 and Harth et al, (1999) /. Exp. Med. 189, 1425-1435).
  • An enzyme that plays a central role in nitrogen metabolism in every cell glutamine synthetase is one of 10 proteins released in large quantity into the bacterium's extracellular milieu, whether the bacterium is growing axenically or intraphagosomally in human mononuclear phagocytes, the primary host cells (see e.g.
  • Antisense oligodeoxyribonucleotides which can base pair with a gene's transcript, constitute a new technology for the control of gene expression in prokaryotes and eukaryotes, including mammalian cells (Zamecnik et al., (1978) Proc. Natl. Acad. Sci. USA 75, 280-284 and Stephenson et al, (1978) Proc. Natl. Acad. Sci. USA 75, 285-288).
  • this technology shows promise as a means for developing new chemotherapeutic agents against human diseases (Zamecnik et al., Antisense Nucleic Acid Drug Dev. (1997) 7, 199-202).
  • antisense ODNs have been used in vitro to inhibit the replication of such pathogens as Plasmodium falcipamm, Toxoplasma gondii, and HIV (Barker et al., (1996) Proc. Natl. Acad. Sci. USA 93, 514-518; Nakaar et al, (1999) /. Biol. Chem. 274, 5083-5087 and Lisziewicz et al, (1992) Proc. Natl. Acad. Sci.
  • an mRNA or DNA target of the M. tuberculosis genome is selected.
  • Polynucleotides are synthesized that are complementary to these targets and at the same time, not homologous to their human counterpart if any. These polynucleotides are then administered to a person infected with . tuberculosis.
  • polynucleotides While a variety of polynucleotides can effect the results provided herein, preference is given to the following polynucleotides that have the strongest propensity to remain in a linear configuration since, in the case of the mRNA of glutamine synthetase, the inhibitory capacity was directly related to the propensity of the polynucleotide to remain in a linear configuration. Such a propensity to remain in a linear configuration can be determined by a number of methods known in the art such as by using the SIGMA-GENOSYS OLIGO-5 SECONDARY STRUCTURE ANALYSIS PROGRAM. Moreover, preference is given to polynucleotides that are complementary to the coding region of the protein since, in the case of the M.
  • tuberculosis aroA gene only the one PS-ODN of four that was complementary to the coding region was inhibitory of M. tuberculosis growth.
  • the glutamine synthetase antisense PS-ODNs disclosed herein exhibit three simultaneous effects on M. tuberculosis: reduction in intracellular and extracellular glutamine synthetase activity, reduction in the formation of the poly-L- glutamate/glutamine cell wall structure, and inhibition of bacterial growth. Except that it acts almost exclusively on extracellular glutamine synthetase, the glutamine synthetase inhibitor L-rnetHonine-J-sulfoxiinine exerts parallel effects on M. tuberculosis. On the basis of studies with this inhibitor (Harth et al., (1999) /. Exp. Med.
  • tuberculosis might subvert host cell function - release of portions of its cell wall poly-L-glutamate/glutamine heteropolymer (Green, H. (1993) Cell 74, 955-956; Karpuj et al., (1999) Proc. Natl. Acad. Sci. USA 96, 7388-7393 and Kazantsev et al., (1999) Proc. Natl. Acad. Sci. USA 96, 11404-11409).
  • tuberculosis glutamine synthetase mRNA transcript but mismatched at 2-4 nucleotide positions with the M. smegmatis glutamine synthetase transcript inhibited expression of the recombinant M. tuberculosis enzyme but not the endogenous M. smegmatis enzyme in M. smegmatis.
  • one mismatch was tolerated since a PS-ODN mismatched at one nucleotide with the M. tuberculosis mRNA transcript inhibited both expression of the enzyme in M. tuberculosis and bacterial growth to the same extent as its perfectly matched PS-ODN counterpart.
  • antisense PS-ODNs can add to the inhibitory effect of conventional antibiotics.
  • antisense PS-ODNs provided an incremental increase in inl ibition of M. tuberculosis growth. Tuberculosis is typically treated with a cocktail of antibiotics to prevent the emergence of resistant organisms, which arise at a frequency of 10 6 to 10 7 to conventional drugs.
  • Antisense polynucleotides against mRNA or DNA targets of M. tuberculosis can be adrninistered to people with active tuberculosis or people harboring M. tuberculosis in a latent state as evidenced by a positive diagnostic test for this organism.
  • the polynucleotides can be administered by any number of routes such as intravenously, intramuscularly, intraperitoneally, subcutaneously, orally, etc.
  • the polynucleotides can inhibit the growth of the M. tuberculosis and thereby treat active tuberculosis or prevent latent tuberculosis from reactivating. Since the polynucleotides were particularly effective against M. tuberculosis entering the stationary phase of growth in vitro, treatment with PS-ODNs may be particularly efficacious against latent infection with tuberculosis.
  • a typical illustrative embodiment consists of a method for inhibiting Mycobacterium tuberculosis glutamine synthetase protein expression by contacting a Mycobacterium tuberculosis bacterium with an effective amount of an antisense polynucleotide that hybridizes to a Mycobacterium tuberculosis glutamine syntiietase polynucleotide, wherein the antisense polynucleotide hybridizes to a region of the Mycobacterium tuberculosis glutamine synthetase polynucleotide encoding the glutamine synthetase protein, thereby inhibiting Mycobacterium tuberculosis glutamine synthetase protein expression.
  • an effective amount of the therapeutic composition is determined based on the intended goal, in this context, the inhibition of protein expression.
  • the goal may be to contact Mycobacterium tuberculosis with an effective amount of an antisense polynucleotide capable of inhibiting the proliferation of Mycobacterium tuberculosis.
  • Means for determining an effective amount sufficient to achieve a goal such as the inhibition of protein expression or the inhibition of bacterial growth are well known in the art and typical assays to measure such factors are provided in the examples below.
  • the quantity to be ac____ both according to number of treatments and unit dose, depends on the protection desired. Precise amounts of the therapeutic composition also depend on the judgment of the practitioner and are peculiar to each individual. Factors affecting dose include physical and clinical state of the patient, the route of a ⁇ _m__ ⁇ istration and the potency, stability and toxicity of the particular therapeutic substance.
  • the antisense polynucleotide has a modification to its internucleoside phosphates linkages such as phosphorothioates, methylphosphonates, phosphoroboronates, phosphoromorpholidates, butyl amidates, and peptide nucleic acid linkages.
  • a number of representative polynucleotides targeting different regions of selected Mycobacterium tuberculosis genes include 5'-GAC GTC GTC GGG CGT CTT-3' (SEQ ID NO: 18), 5'-CAT GCC GGA CCC GTT GTC GCC-3' (SEQ ID NO: 19) and 5'-CCA CAG CGA CTG ATG ACA GTG CAT-3' (SEQ ID NO: 20) which are specific for glutamine synthetase.
  • Another embodiment of the invention consists of contacting the Mycobacterium tuberculosis with an effective amount of a second antisense polynucleotide that hybridizes to a Mycobacterium tuberculosis glutamine synthetase polynucleotide, wherein the second antisense polynucleotide hybridizes to a region of the Mycobacterium tuberculosis glutamine synthetase polynucleotide encoding the glutamine synthetase protein that is distinct from the region targeted by the first antisense oligonucleotide.
  • a second antisense polynucleotide that hybridizes to a different Mycobacterium tuberculosis polynucleotide, for example an mRNA or gene selected from the group consisting of aroA, ask, groES and the genes of the Antigen 85 complex.
  • Yet another embodiment consists of combination therapy as is known in the art, for example contacting the Mycobacterium tuberculosis with an effective amount of an antibiotic capable of inhibiting the proliferation of Mycobacterium tuberculosis.
  • the antibiotic is selected from the group consisting of rifampin, isoniazid, amikacin, ethambutol and polymyxin B nonapeptide.
  • Yet another embodiment consists of an antisense compound of about 15 to about 50 nucleobases in length targeted to a portion of a nucleic acid molecule encoding a Mycobacterium tuberculosis protein such as the glutamine synthetase protein, wherein the antisense compound specifically hybridizes with the nucleic acid molecule encoding the protein, thereby inhibiting expression of the protein.
  • the antisense compound is an antisense oligonucleotide such as one of the antisense polynucleotides provided herein.
  • the antisense polynucleotide has at least one modified internucleoside linkage such as a phosphorothioate linkage.
  • the antisense polynucleotide has a complete homology with the nucleic acid molecule encoding the Mycobacterium tuberculous glutamine synthetase protein.
  • Yet another embodiment of the invention consists of a process for producing an antisense compound that inhibits the expression of any Mycobacterium tuberculosis protein such as glutamine synthetase.
  • an antisense compound that inhibits the expression of any Mycobacterium tuberculosis protein such as glutamine synthetase.
  • a antisense polynucleotide typically about 15 to about 50 nucleobases in length
  • a antisense polynucleotide typically about 15 to about 50 nucleobases in length
  • a next step in this process entails contacting a culture of Mycobacterium tuberculosis with an effective amount of the antisense polynucleotide under conditions such that the antisense polynucleotide hybridizes with the targeted Mycobacterium tuberculosis polynucleotide.
  • a next step in this process entails comparing the levels of Mycobacterium tuberculosis protein expression (i.e. the protein encoded by the targeted polynucleotide) in the culture contacted with the effective amount of the antisense polynucleotide to the levels of Mycobacterium tuberculosis protein expression in a control culture of Mycobacterium tuberculosis not contacted with the antisense polynucleotide.
  • the skilled artisan understands that protein expression in a control culture oi Mycobacterium tuberculosis not contacted with an antisense polynucleotide (i.e.
  • a next step in this process entails determining whether the antisense polynucleotide inhibits the expression of the targeted protein by observing the level of that protein's expression in the Mycobacterium tuberculosis culture contacted with the antisense polynucleotide relative to the level of that protein's expression in the Mycobacterium tuberculosis control culture.
  • a closely related embodiment of this invention consists of an antisense polynucleotide produced according to this process.
  • M. tuberculosis strain Erdman ATCC 35801
  • M. smegmatis l-2c Garbe et al., (1994) Microbiol. 140, 133-138) were cultured in 7H9 medium (Difco) supplemented with 2% glucose at 37°C.
  • M. tuberculosis was maintained in a 5% C ⁇ 2-95% air atmosphere as unshaken cultures (because of safety considerations) and M. smegmatis was maintained at ambient conditions with vigorous shaking.
  • smegmatis were cultured in duplicate in 1 ml, 2 ml, or 5 ml of 7H9 broth in polystyrene tabes (Fisher) or tissue culture flasks (Costar) in the presence of medium alone, PS-ODNs at final concentrations of 0.1, 1, or 10 ⁇ M, or PS- ODNs plus inhibitory and/ or subinhibitory concentrations of the antibiotics amikacin (0.058, 0.58, and 5.8 ⁇ g/ml), ethambutol (0.1, 0.25, and 0.5 ⁇ g/ml), or polymyxin B nonapeptide (0.1, 0.25, 0.5 ⁇ g/ml). All antibiotics were from Sigma.
  • the minimal inhibitory concentrations (MIC) of the antibiotics for M. tuberculosis Erdman and M. smegmatis l-2c were established in bacterial cultures grown under the same conditions in the presence of antibiotics ranging in concentration from 0.01 - 32 ⁇ g/ml for amikacin and 0.1 - 25 ⁇ g/ml for ethambutol and polymyxin B nonapeptide.
  • MIC minimal inhibitory concentrations
  • Three target sites for the binding of the antisense PS-ODNs were chosen (Table 1).
  • Antisense PS-ODNs were synthesized on a 394 DNA/RNA synthesizer (Applied Biosystems) using standard phosphoroamidite chemistry.
  • PS-ODNs were introduced by oxidation with the Beaucage thiolating reagent (Padmapriya et al, (1994) Antisense Res. Develop. 4, 185-199) and assembled PS-ODNs were purified by HPLC and lyophilized. Amikacin derivatives were synthesized by a phosphorothioate based methodology, linking the antibiotic via one of its amino groups to a phosphate residue at the end of a 3' attached 18-atom spacer arm. PS-ODN stock solutions were prepared just prior to their use and added to mycobacterial cultures after filter sterilization through 0.45 ⁇ m HT Tuffryn membrane filters (German Sciences).
  • M. tuberculosis contains four genetic loci with domains that exhibit homologies to glutamine synthetase genes from other bacteria (see e.g. Harth et al., (1994) Proc. Natl. Acad. Sci. USA 91, 9342-9346 and Cole et al., (1998) Nature 393, 537-544).
  • Harth et al. (1994) Proc. Natl. Acad. Sci. USA 91, 9342-9346 and Cole et al., (1998) Nature 393, 537-544.
  • glnh ⁇ only one gene, designated glnh ⁇ and located at map position Rv2220 of the M.
  • tuberculosis H37Rv genome (Cole et al., (1998) Nature 393, 537-544), expresses an active glutamine synthetase.
  • This enzyme has an apparent molecular mass of ⁇ 680,000 Da (12 subunits of ⁇ 56,000 Da each) (see e.g. Harth et al., (1994) Proc. Natl. Acad. Sci. USA 91, 9342-9346). It is not known if the other loci (glnA2, gln b, glnA4) axe expressed. M.
  • tuberculosis and other pathogenic mycobacteria of the tuberculosis complex express large amounts of the enzyme and export a large proportion of what is produced - one-third in the case of M. tuberculosis (see e.g. Harth et al, (1994) Proc. N ⁇ tl. Ac ⁇ d. Sci. USA 91, 9342-9346 and Harth et al, (1997) /. Biol. Chem. 272, 22728-22735).
  • Nonpathogenic mycobacteria such as M. smegmatis and M.
  • phlei typically exhibit a lower glutamine synthetase expression level than pathogenic mycobacteria and export less than 1/100th of the total glutamine synthetase produced (see e.g. Harth et al., (1994) Proc. Natl. Acad. Sci. USA 91, 9342-9346). To date, it is unknown if the nonpathogenic mycobacteria share a similar genomic arrangement of glutamine synthetase specific DNA loci. Because the rate of transcription under standard growth conditions is nearly constant (see e.g. Harth et al., (1997) /. Biol. Chem. 272, 22728-22735) and because the downstream effects of inhibition by antisense PS-ODNs, i. e. a decrease in the amount of detectable enzyme and its activity, can be tracked continuously and quantitatively, the glutamine synthetase transcript is a logical target to study regulation of gene expression by antisense PS-ODNs.
  • the glutamine synthetase coding region contains 1,434 base pairs, excluding the stop codon.
  • the primary transcript under standard axenic growth conditions is 1,500 - 1,600 nucleotides in length (see e.g. Harth et al, (1997) /. Biol. Chem. 272, 22728-22735).
  • Based on densitometric analyses of our Northern hybridizations we calculated that ⁇ 11 glutamine synthetase gene transcripts of ⁇ 1,550 nucleotides are present per cell.
  • tuberculosis genome [ 4.4 x 10 6 base pairs (Cole et al, (1998) Nature 393, 537- 544)] very unlikely; moreover, partial hybridization of short sequences witiiin such PS- ODNs, while theoretically possible, would likely be unstable.
  • Example 3 Specificity of antisense PS-ODNs for M. tuberculosis glutamine synthetase mRNA.
  • the aligned RNA sequences demonstrate that the target site for PS-ODN #4-9 is different in 3 nucleotide positions (5'-AAG ACG CCC GAC GAC GUC-3' (SEQ ID NO: 1) for M. tuberculosis and 5'-AAG ACG UCG GAC GAC AUC-3' (SEQ ID NO: 4) for M. smegmatis), the target site for PS- ODN #269-275 is different in 2 nucleotide positions (5'-GGC GAC AAC GGG UCC GGC AUG-3' (SEQ ID NO: 2) for M. tuberculosis and 5'-GGC GAC AAC GGU UCG GGC AUG-3' (SEQ ID NO: 5) for M.
  • M. tuberculosis l-2c wildtype strain and its recombinant isotype expressing the M. tuberculosis Erdman glutamine synthetase from a mycobacterial shuttle vector Harth et al., (1997) /. Biol. Chem. 272, 22728-22735).
  • tuberculosis enzyme activity decreased from 12.4 mU in uninhibited cultures to 11.7 mU for cultures growing in the presence of PS-ODN #4-9, to 11.4 mU in the presence of PS-ODN #275-282, to 11.0 mU in the presence of PS-ODN #269-275, and to 10.7 mU in the presence of all 3 PS-ODNs (Fig 2C). Assuming the entire 1.7 mU decrease in cellular enzyme activity in the presence of 3 PS-ODNs was in the fraction of enzyme activity due to recombinant M.
  • tuberculosis glutamine synthetase ( ⁇ 5 mU in a total of 12.4 mU), this fraction of activity was decreased 34%, similar to the decrease observed in M. tuberculosis cultures.
  • tuberculosis glutamine synthetase decreased from 61.9 mU in uninhibited cultures to 55.2 mU in the presence of PS-ODN #4-9, to 47.3 mU in the presence of PS-ODN #275-282, to 44.6 mU in the presence of PS-ODN #269-275, and to 36.7 mU in the presence of all 3 PS-ODNs (S.D. ⁇ 15% for all data).
  • the 41% reduction in the presence of all 3 PS-ODNs was similar to the decrease observed in M. tuberculosis cultures (Fig. 2D). Again, the inhibitory capacity of each PS- ODN correlated directly with its propensity to remain in a linear conformation as described above for the M.
  • Example 4 Effect of PS-ODNs on glutamine synthetase activity and expression.
  • Proteins were analyzed by denaturing polyacrylamide gel electrophoresis followed by staining with Coomassie brilliant blue R, and protein concentrations were determined by the bicinchoninic acid reagent (Pierce).
  • the possibility of leakage of cytoplasmic glutamine synthetase from dead or dying mycobacteria was assessed by monitoring the activity of the cytoplasmic marker protein lactate dehydrogenase during the 6 week/6 day growth period both in the culture medium and in the cell pellet, using a commercially available diagnostic kit (Sigma). Extracellular lactate dehydrogenase activity never exceeded 0.2% of intracellular activity.
  • PS-ODN #269-275 has a strong potential to maintain a linear structure
  • PS-ODN #275-282 has a moderate potential to do so
  • PS-ODN #4-9 has a weak potential to maintain a linear structure
  • the activity decreased from 25.8 mU under standard growth conditions to 17.1 mU in the presence of PS-ODN #4-9, 15.6 mU in the presence of PS-ODN #275-282, and 15.1 mU in the presence of PS-ODN #269-275.
  • Combinations of 2 PS-ODNs were not significantly more inhibitory than 1 PS-ODN; however, the combination of all 3 PS-ODNs decreased enzyme activity to 13.3 mU, a reduction of 50% below the level of an uninhibited culture (S.D. ⁇ 10% for all data).
  • PS-ODNs tethered to an amikacin moiety in theory to guide PS- ODNs to the ribosomes, had no greater inhibitory effect than PS-ODNs not tethered to amikacin in this as well as in all subsequent studies.
  • Example 5 Effect of PS-ODNs on the amount of cell wall poly-L- glutamate/glutamine.
  • tuberculosis grown in the presence of various antisense and control PS-ODNs at their effective concentration of 10 ⁇ M for 6 weeks by which time the bacteria had reached stationary phase.
  • the heteropolymer was isolated from the mycobacterial cell wall to a purity of 90 - 95% and, along with the co-purified mycobacterial peptidoglycan moiety, subjected to total amino acid hydrolysis (Table 2).
  • PS-ODNs #4-9 or #269-275 separately or in combination, reduced the amount of poly-L-glutamate/glutamine from 50.3 ⁇ g per 1 x 10 10 cells in untreated control cultures to 46.7 ⁇ g in the presence of PS-ODN #4-9, to 43.5 ⁇ g in the presence of PS-ODN #269-275, and to 38.3 ⁇ g in the presence of both PS-ODNs.
  • the combination of all control PS-ODNs together did not significantly decrease the amount of this structure (Table 2).
  • the decrease in poly-L-glutamate/glutamine (23.8 ⁇ 3.1%) compares favorably with the decrease in detectable extracellular glutamine synthetase activity described above.
  • PS-ODNs decreased the amount of D,L-ala_ ⁇ ine (present in equimolar amounts) in the peptidoglycan fraction (>90% homogeneous) from 20.5 ⁇ g per 1 x 10 10 cells in control cultures to 19.0 ⁇ g in the presence of PS-ODN #4-9, to 18.5 ⁇ g in the presence of PS-ODN #269-275, and to 17.4 ⁇ g in the presence of both PS- ODNs, a reduction of 15.1 ⁇ 0.3%.
  • the combination of all control PS-ODNs did not decrease the amount of this structure.
  • Example 6 Effect of PS-ODNs on the growth of M. tuberculosis and M. smegmatis.
  • Example 7 Effect of combinations of anti-tuberculosis drugs and glutamine synthetase antisense ODNs o M. tuberculosis and ⁇ . smegmatis proliferation.
  • anti-tuberculosis drugs such as isoniazid or ethambutol
  • M. tuberculosis see e.g. Mdluli et al., (1998) Science 280, 1607- 1610 and Telenti et al, (1997) Nat. Med. 3, 567-570).
  • the damage in tiie mycobacterial cell wall becomes so extensive that the bacteria can no longer control influx and efflux of ions, proteins, and other vital cellular components, and the bacteria subsequently lyse.
  • subinhibitory concentrations of such drugs might "soften" the cell wall and promote the influx of PS-ODNs, thereby enhancing their effectiveness.
  • Two drugs, ethambutol and polymyxin B nonapeptide were chosen for this purpose.
  • MIC minitnal inhibitory concentrations
  • PS-ODNs against the aroA gene were tested, all at 10 ⁇ M: Val 23:5'-TGGGGCTGGCCATGTCTTCAC-3' (SEQ ID NO: 7) 21-mer fully complementary to nucleotides 1-21 of the aroA gene starting from the start codon. Strong propensity to remain linear.
  • Val 24:5'-CGCTTCATCCTGCCGTGTCGG (SEQ ID NO: 8) 21-mer fully complementary to nucleotides -21 to -1 of the upstream non-coding sequence of the aroA gene. Moderate propensity to remain linear.
  • Val 25:5'-TGGCCATGTCTTCACCGCTTCATCCTG (SEQ ID NO: 9) 27-mer fully complementary to nucleotides -12 to 15 of the aroA gene. Strong propensity to remain linear.
  • Val 26:5'-CCATGTCTTCACCGCTTCATCCTG (SEQ ID NO: 10) 24-mer fully complementary to nucleotides -12 to 12 of the aroA gene. Moderate propensity to remain linear.
  • Val 33 (aka ODS 33): 5'-TGCCGCAGCCACGGCGACGGCCGTGGT (SEQ ID NO: 11) 27-mer complementary to the nucleotide sequence 466-492 of the ask gene (Mismatched at 5 nucleotides, but 2 involve potentially stable C:C base pairs) (This 27- mer is fully complementary to the nucleotide sequence 1527-1553 of the M. smegmatis ask-asd operon).
  • Val 34 (aka ODS 55): 5'-TGCCGCAGCCACGGCGACGGCCGTGGTGTCCGAACC (SEQ ID NO: 12) 36-mer complementary to the nucleotide sequence 457-492 of the ask gene (Mismatched at 6 nucleotides, but 2 involve potentially stable C:C base pairs) (This 36-mer is fully complementary to the nucleotide sequence 1518-1553 of the M. smegmatis ask-asd operon).
  • Val 41 5'-CACCTTCGCCACGATTGGAGCCCTCCA (SEQ ID NO: 13) 27-mer complementary to the nucleotide sequence -15 to 12 of the ⁇ raE-. gene.
  • Val 23 inhibited Af. tuberculosis growth in the absence of antibiotic. It enhanced the inhibition of M. tuberculosis m. the presence of antibiotic.
  • Val 24 did not inhibit M. tuberculosis growth in the absence of antibiotic. It enhanced the inhibition of Af. tuberculous in. the presence of antibiotic.
  • Val 25 did not inhibit Af. tuberculosis growth in the absence of antibiotic nor enhance the inhibition of Af. tuberculosis m. the presence of antibiotics.
  • Val 26 did not inhibit Af. tuberculosis growth in the absence of antibiotic. It enhanced the inhibition of Af. tuberculosis in the presence of antibiotic.
  • Val 33 inhibited Af. tuberculosis growth in the absence of antibiotic. It enhanced the inhibition of Af. tuberculosis m. the presence of antibiotic.
  • Val 34 inhibited Af. tuberculosis growth in the absence of antibiotic. It enhanced the inhibition of Af. tuberc ulo ⁇ s in the presence of antibiotic.
  • Val 41 did not inhibit Af. tuberculosis growth in the absence of antibiotic. It enhanced the inhibition of Af. tuberculosis hi the presence of antibiotic.
  • Figure 5 shows a graph of Val 23 with and without Ethambutol (ETH) (5 ⁇ g /ml).
  • Figure 6 shows a graph of Val 24 with and without Ethambutol (ETH) (5 ⁇ g /ml).
  • Figure 7 shows a graph of Val 25 with and without Ethambutol (ETH) (5 ⁇ g /ml).
  • Figure 8 shows a graph of Val 26 with and without Ethambutol (ETH) (5 ⁇ g
  • Figure 9 shows a graph of Val 33 with and without Ethambutol (ETH) (5 ⁇ g /ml).
  • Figure 10 shows a graph of Val 34 with and without Ethambutol (ETH) (5 ⁇ g /ml).
  • Figure 11 shows a graph of Val 41 with and without Ethambutol (ETH) (5 ⁇ g /ml).
  • Example 9 PS-ODNs directed against the 30/32 kDa protein complex genes of M. tuberculosis
  • nucleotides 276-303 of the 32A kDa protein gene (numbered from the entire coding region including leader sequence) (No mismatches); b) nucleotides 267-294 of the 30 kDa protein gene (Mismatched at position 276); c) nucleotides 279-306 of the 32B kDa protein gene (Mismatched at position 303).
  • Af. tuberculosis Erdman strain was grown in 7H9 medium to an Optical Density (O.D.) at 540 nm of 0.5, sonicated, diluted in 7H9 medium to an O.D. of approximately 0.05, and 2 ml of the suspension was added to replicate 12x75 mm plastic test tubes. Three set of tabes were prepared. Set 1: The PS-ODN described above at a final concentration of 10 ⁇ M or control buffer was added to each tube in duplicate once only at the start of the experiment. Set 2: The PS-ODN described above at a final concentration of 10 ⁇ M or control buffer was added to each tabe in duplicate weekly for 9 weeks.
  • O.D. Optical Density
  • Figure 12 shows a graph of ML10 with and without Ethambutol (ETH) (5 ⁇ g
  • PS-ODNs The following PS-ODNs were tested, all at 10 ⁇ M:
  • Af. tuberculosis Erdman strain was grown in 7H9 medium to an Optical Density (O.D.) at 540 nm of 0.5, sonicated, diluted in 7H9 medium to an O.D. of approximately 0.05, and 2 ml of the suspension was added to replicate 12x75 mm plastic test tabes.
  • a single PS-ODN among the three listed above at a final concentration of 10 ⁇ M or control buffer was added to each tube. The cultures were incubated for 6 weeks. Growth of Af. tuberculosis was assayed by obtaining O.D. measurements weekly and enumerating colony forming units on 7H11 agar medium.
  • Fig. 13 shows that 269-275-DAO was more effective at lO ⁇ M than PS-ODN 269-275 at inhibiting the growth of Af. tuberculosis.
  • the control ODN yielded no inhibition of growth, Le. it was equivalent to no ODN being added.
  • Fig. 14 shows that 269-275-DAO does not inhibit Af. smegmatis.
  • PS-ODNs The following PS-ODNs were tested, all at 10 ⁇ M:
  • Af. tuberculosis Erdman strain was grown in 7H9 medium to an Optical Density (O.D.) at 540 nm of 0.5, sonicated, diluted in 7H9 medium to an O.D. of approximately 0.05, and 2 ml of the suspension was added to replicate 12x75 mm plastic test tubes.
  • a single PS-ODN among the six listed above at a final concentration of 10 ⁇ M or control buffer was added to each tabe. The cultures were incubated for 6 weeks. Growth of Af. tuberculosis was assayed by obtaining O.D. measurements weekly and enumerating colony forming units on 7H11 agar medium.
  • Fig. 15 shows that only 5N-269-275 PS-ODN was more effective than PS-ODN 269- 275 and that there was a trend toward greater inhibition with higher "N" groups. (5N> 4N> 3N/2N/1 N).
  • Fig. 16 shows the six ODNs tested in this experiment.
  • PS-ODN phosphorothioate modified oligodeo_-y_ibonu_leotide
  • ⁇ / «Al glutamine synthetase gene
  • [nt] nucleotide(s)

Abstract

L'invention concerne des procédés pour inhiber la prolifération de Mycobacterium tuberculosis, comprenant la mise en contact de Mycobacterium tuberculosis avec une quantité suffisante de polynucléotide complémentaire d'un transcrit mRNA exprimé par Mycobacterium tuberculosis. Selon l'invention, les procédés utilisent des polynucléotides antisens modifiés au phosphorothioate (PS-ODNs) dirigés contre le mRNA des gènes Mycobacterium tuberculosis, tels que la glutamine synthétase, aroA,ask, groES, et les gènes du complexe antigénique 85.
PCT/US2000/034688 1999-12-22 2000-12-20 Traitement de mycobacterium tuberculosis avec des polynucleotides antisens WO2001046473A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/168,244 US20040033972A1 (en) 2000-12-20 2000-12-20 Treatment of mycobacterium tuberculosis with antisense polynucleotides
AU24446/01A AU2444601A (en) 1999-12-22 2000-12-20 Treatment of mycobacterium tuberculosis with antisense polynucleotides
PCT/US2002/015963 WO2002094848A1 (fr) 2000-12-20 2002-05-20 Traitement du bacille de koch au moyen d'oligonucleotides antisens

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17192999P 1999-12-22 1999-12-22
US60/171,929 1999-12-22

Publications (1)

Publication Number Publication Date
WO2001046473A1 true WO2001046473A1 (fr) 2001-06-28

Family

ID=22625679

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/034688 WO2001046473A1 (fr) 1999-12-22 2000-12-20 Traitement de mycobacterium tuberculosis avec des polynucleotides antisens

Country Status (2)

Country Link
AU (1) AU2444601A (fr)
WO (1) WO2001046473A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592250B2 (en) 2002-02-01 2017-03-14 Life Technologies Corporation Double-stranded oligonucleotides
US9777275B2 (en) 2002-02-01 2017-10-03 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014613A1 (fr) * 1996-10-02 1998-04-09 Regents Of The University Of California Procedes et agents prophylactiques et chimiotherapeutiques a ciblage externe

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014613A1 (fr) * 1996-10-02 1998-04-09 Regents Of The University Of California Procedes et agents prophylactiques et chimiotherapeutiques a ciblage externe

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARTH G. ET AL.: "Treatment of mycobacterium tuberculosis with antisense oligonucleotides to glutamine synthetase mRNA inhibits glutamine synthetase activity, formation of the poly-L-glutamate/glutamine cell wall structure and bacterial replication", PROC. NATL. ACAD. SCI. USA, vol. 97, no. 1, 4 January 2000 (2000-01-04), pages 418 - 423, XP002938271 *
RAPAPORTE E. ET AL.: "Antimycobacterial activities of antisense oligodeoxynucleotide phosphorothioates in drug-resistant strains", PROC. NATL. ACAD. SCI. USA, vol. 93, January 1996 (1996-01-01), pages 709 - 713, XP002938272 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9592250B2 (en) 2002-02-01 2017-03-14 Life Technologies Corporation Double-stranded oligonucleotides
US9777275B2 (en) 2002-02-01 2017-10-03 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US9796978B1 (en) 2002-02-01 2017-10-24 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US10036025B2 (en) 2002-02-01 2018-07-31 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US10106793B2 (en) 2002-02-01 2018-10-23 Life Technologies Corporation Double-stranded oligonucleotides
US10196640B1 (en) 2002-02-01 2019-02-05 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency
US10626398B2 (en) 2002-02-01 2020-04-21 Life Technologies Corporation Oligonucleotide compositions with enhanced efficiency

Also Published As

Publication number Publication date
AU2444601A (en) 2001-07-03

Similar Documents

Publication Publication Date Title
US7148204B2 (en) Antisense modulation of bcl-x expression
US6136603A (en) Antisense modulation of interleukin-5 signal transduction
US7288530B2 (en) Antisense modulation of survivin expression
CA2803882A1 (fr) Traitement de maladies liees a la sous-unite alpha du canal sodique voltage-dependant (scna) par inhibition du produit de transcription naturel antisens a la scna
US20210163950A1 (en) Treatment of angiopoietin like 7 (angptl7) related diseases
CA2345209C (fr) Modulation antisens de l'expression de l'integrine alpha 4
CA2584614A1 (fr) Modulation antisens de l'expression de l'integrine .alpha.4
US6087489A (en) Antisense oligonucleotide modulation of human thymidylate synthase expression
US20030055015A1 (en) Antisense modulation of expression of tumor necrosis factor receptor-associated factors (TRAFs)
US20040033972A1 (en) Treatment of mycobacterium tuberculosis with antisense polynucleotides
JPH11512601A (ja) 修飾プロテインキナーゼａ特異的オリゴヌクレオチドおよびその使用法
WO2001046473A1 (fr) Traitement de mycobacterium tuberculosis avec des polynucleotides antisens
US20060183676A1 (en) Treatment of mycobacterium tuberculosis with antisense oligonucleotides
WO2004093778A2 (fr) Oligonucleotides bloquant les recepteurs de type toll
EP1238069A2 (fr) Oligonucleotides de recepteur type 1 de glutamate metabotropique (mglur1)
US7393950B2 (en) Antisense oligonucleotides targeted to human CDC45
US8318922B2 (en) Treatment and prevention of hyperproliferative conditions in humans and antisense oligonucleotide inhibition of human replication-initiation proteins
US7465714B2 (en) Oligonucleotide inhibitors of MBD2/DNA demethylase and uses thereof
US20060089322A1 (en) Antisense oligonucleotides for identifying drug targets and enhancing cancer therapies
US20080255066A1 (en) Antisense oligonucleotide strategies for the enhancement of cancer therapies
WO2011112516A1 (fr) Traitement et prévention de l'infection par le virus de l'hépatite c en utilisant des oligonucléotides antisens de la kinase c-raf
US20060135450A1 (en) Combinations of antisense oligonucleotides directed against thymidylate synthase mrna and uses thereof
US20040147471A1 (en) Antisense modulation of TNFR1 expression
WO2005021776A2 (fr) Methodes d'utilisation d'une rnase h de mammifere et de compositions a base de celle-ci
KR20230107296A (ko) 촉매 서열에 기반한 박테리아 감염을 치료 또는 예방하는 방법

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10168244

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP